Get started
Author

Gaetana Capobianco

RD‐CODOX‐M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B‐cell lymphoma
2011 · Gaetano Corazzelli, Ferdinando Frigeri, et al. · British Journal of Haematology · 82
Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma
2009 · Gaetano Corazzelli, Gaetana Capobianco, et al. · Cancer Chemotherapy and Pharmacology · 80
Biweekly rituximab, cyclophosphamide, vincristine, non‐pegylated liposome‐encapsulated doxorubicin and prednisone (R‐COMP‐14) in elderly patients with poor‐risk diffuse large B‐cell lymphoma and moderate to high ‘life threat’ impact cardiopathy
2011 · Gaetano Corazzelli, Ferdinando Frigeri, et al. · British Journal of Haematology · 59
PDF
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma
2014 · Luigi Aloj, Laura D’Ambrosio, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 36
Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma
2009 · Gaetano Corazzelli, Rosaria De Filippi, et al. · American Journal of Hematology · 32
PDF
Pentostatin (2'-deoxycoformycin) for the treatment of hepatosplenic gammadelta T-cell lymphomas.
2005 · Gaetano Corazzelli, Gaetana Capobianco, et al. · PubMed · 30
Circulating dendritic cells deficiencies as a new biomarker in classical Hodgkin lymphoma
2018 · Domenico Galati, Serena Zanotta, et al. · British Journal of Haematology · 19
PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas
2016 · Renato Franco, Giosuè Scognamiglio, et al. · Oncotarget · 14
PDF
Elevation of clonal serum free light chains in patients with HIV‐negative primary effusion lymphoma (PEL) and PEL‐like lymphoma
2009 · Rosaria De Filippi, Giancarla Iaccarino, et al. · British Journal of Haematology · 14
Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin's lymphoma
2007 · Filippo Russo, Secondo Lastoria, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 14
Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial.
2010 · Gaetano Corazzelli, Ferdinando Frigeri, et al. · Blood · 13
A phase II study of dose‐dense and dose‐intense ABVD ( ABVD DD‐DI) without consolidation radiotherapy in patients with advanced H odgkin lymphoma
2014 · Filippo Russo, Gaetano Corazzelli, et al. · British Journal of Haematology · 12
Abnormally Elevated Levels of Serum Free-Immunoglobulin Light Chains Are Frequently Found in Classic Hodgkin Lymphoma (cHL) and Predict Outcome of Patients with Early Stage Disease.
2009 · Rosaria De Filippi, Filippo Russo, et al. · Blood · 12
A Case of Congenital Dyserythropoietic Anemia Type II, Gilbert's Syndrome and Malleolar Trophic Ulcers
2002 · Bruno Bordi, Maria Rosaria D'Amico, et al. · Hematology · 6
Long‐term efficacy and safety of dose‐dense and dose‐intense ABVD without consolidation radiotherapy in patients with advanced Hodgkin lymphoma: A 15‐year follow‐up of the ABVDDD‐DI phase II study
2024 · Gaetano Corazzelli, Annarosa Cuccaro, et al. · British Journal of Haematology · 3
Dose-Dense(dd) ABVD and Dose-Dense/Dose-Intense(dd-di) ABVD in Newly Diagnosed Patients (pts), Intermediate- and Advanced-Stage with Classical Hodgkin's Lymphoma (cHL): Final Results.
2009 · Filippo Russo, Gaetano Corazzelli, et al. · Blood · 3
Gemcitabine, Ifosfamide, Oxaliplatin and Rituximab (R-GIFOX), a New Effective Cytoreductive/Mobilizing Salvage Regimen for Relapsed and Refractory Aggressive Non-Hodgkin’s Lymphoma: Results of a Pilot Study.
2005 · Gaetano Corazzelli, Filippo Russo, et al. · Blood · 3
The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones
2015 · Rosaria De Filippi, Stefania Crisci, et al. · Blood · 2
Use of the cumulative amount of serum-free light chains (sFLC) at diagnosis and PET2 for the early identification of high risk of treatment failure in Hodgkin lymphoma (cHL).
2012 · Rosaria De Filippi, Fortunato Morabito, et al. · Journal of Clinical Oncology · 2
Rituximab Plus Gemcitabine, Ifosfamide, Oxaliplatin (R-GIFOX), a New Effective Cytoreductive/Mobilizing Salvage Regimen for Relapsed and Refractory Hodgkin Lymphoma
2008 · Gaetano Corazzelli, Gaetana Capobianco, et al. · Blood · 2
Dose- and time-intensified ABVD without radiotherapy (RT) for advanced-stage Hodgkin lymphoma (HL) with mediastinal bulky disease (MBD).
2012 · Gaetano Corazzelli, Filippo Russo, et al. · Journal of Clinical Oncology · 1
Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas
2011 · Gaetano Corazzelli, Ferdinando Frigeri, et al. · European Journal Of Haematology · 1
PDF
Cardiotoxicity and Treatment Efficacy of Not Pegilated Liposomal Doxorubicin in Haematological Malignancies: Our Experience.
2007 · Alfredo Gagliardi, Maria Lucia Boffa, et al. · Blood · 1
Cladribine (2-CDA) Plus Sequential Rituximab in Newly Diagnosed Disseminated Extranodal Marginal Zone B-Cell Lymphomas. A Phase II Study.
2006 · Gaetano Corazzelli, Gaetana Capobianco, et al. · Blood · 1
The Impact of Relative Dose Intensity on Response and Survival in a Series of 180 Newly Diagnosed Patients with Hodgkin’s Lymphoma.
2005 · Filippo Russo, Gino Svanera, et al. · Blood · 1
Works count: 33
Citation count: 443
H-index: 12
I10-index: 13
Year
Topic
Type